Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Virus Diseases 1Liver Cirrhosis 1Hepatitis, Viral, Human 1Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

Ultrasonography 2Tomography, X-Ray Computed 2tremelimumab 1lenvatinib 1hepatitis C immune globulin, human 1fluoromisonidazole 1epigallocatechin gallate 1durvalumab 1babao dan 1Vitamin B 6 1Urination 1Tomography 1Tidal Volume 1Rosuvastatin Calcium 1Propranolol 1Probiotics 1Preoperative Exercise 1Positron-Emission Tomography 1Portasystemic Shunt, Transjugular Intrahepatic 1Population Groups 1Plasmapheresis 1Oxaliplatin 1Nadolol 1Mebendazole 1Introns 1Immunoglobulin G 1Glutathione 1Gemcitabine 1Furosemide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Liver Cirrhosis × hepatitis C immune globulin, human × Clear all
NCT01804829 2017-03-15

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Biotest Pharmaceuticals Corporation

Phase 3 Completed
80 enrolled
Gastrointestinal

Hepatitis, Viral, Human, Hepatitis C, Carcinoma, Hepatocellular, Liver Cirrhosis, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡